Autologous Bone Marrow Transplantation - Blog Science Connections

44 ABMTin CRI
program in CR1 is the relatively low number of leukemic cells remaining in the
recipient and the small chance of drug resistance of the leukemic cell
population in CR1. This program is the subject of this chapter.
PATIENT POPULATION
The patients selected for transplantation were those who achieved CR and
stayed in remission for at least 6 months. Their median age was 35 years (range,
17-50 years). The induction and consolidation programs for acute myelogenous
leukemia (AML) and acute lymphocytic leukemia (ALL) are shown in Figures 1
and 2. It should be noted that in AML as well as in ALL, high-dose ara-C
(cytarabine) was used for consolidation immediately after achieving CR. Three
courses of chemotherapy, AD-OAP (Adriamycin-Oncovin [vincristine], ara-C
[cytarabine 1, prednisone) for AML and MTX-DOMP (methotrexate-daunorubicin,
Oncovin [vincristine], mercaptopurine, prednisone) for ALL, were administered
before high-dose intensification with CBV and ABMT. During the chemotherapy
Remission
AP.A-C 3 g/rn^
Induction
PPR >.6 PPR